Zoxazolamine is a centrally acting myorelaxant.It is formerly used as an antispasmodic and uricosuric.
ZSET1446 (ST101) is a novel cognitive enhancer that activates T-type voltage-gated calcium channels (VGCCs), and it significantly improves learning deficits in various types of Alzheimer disease (AD) models.
ZSET1446 (ST101) is a novel cognitive enhancer that activates T-type voltage-gated calcium channels (VGCCs), and it significantly improves learning deficits in various types of Alzheimer disease (AD) models.
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3-kinase (PI3K), induces G1 arrest of the cell cycle in vivo.
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3-kinase (PI3K), induces G1 arrest of the cell cycle in vivo.
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3-kinase (PI3K), induces G1 arrest of the cell cycle in vivo.
ZT-12-037-01 is a potent, selective, ATP-competitive STK19 inhibitor with IC50 values of 23.96 nM and 27.94 nM for STK19 (WT) and STK19 (D89N), respectively.
ZT-12-037-01 is a potent, selective, ATP-competitive STK19 inhibitor with IC50 values of 23.96 nM and 27.94 nM for STK19 (WT) and STK19 (D89N), respectively.
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma.
Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor.
Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor.
Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor.